Free Trial
Les Sulewski

Les Sulewski Analyst Performance

Vice President, Biotech Equity Research at Truist Financial

Les Sulewski is a stock analyst at Truist Financial in the medical sector, covering 8 publicly traded companies. Over the past year, Les Sulewski has issued 13 stock ratings, including buy and hold recommendations. While full access to Les Sulewski's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Les Sulewski's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
90.00% 9 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy90.0%9 ratings
Hold10.0%1 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Les Sulewski at Truist Financial, the majority (90.0%) have been Buy recommendations, followed by 10.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
6 companies
NYSE
25.0% of companies on NYSE
2 companies

Les Sulewski, an analyst at Truist Financial, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Les Sulewski of Truist Financial specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - GENERIC DRG
2 companies
25.0%
MED - BIOMED/GENE
2 companies
25.0%
MED - DRUGS
2 companies
25.0%
MED PRODUCTS
1 company
12.5%
MEDICAL SERVICES
1 company
12.5%

Les Sulewski's Ratings History at Truist Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
4/30/2026Boost Price Target$35.34$45.00Buy
biote Corp. stock logo
BTMD
biote
4/16/2026Lower Price Target$2.05$4.00Buy
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3/5/2026Initiated Coverage$8.20$18.00Buy
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
3/2/2026Boost Price Target$13.81$17.00Buy
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2/18/2026Boost Price Target$34.21$42.00Buy
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2/10/2026Set Price Target$46.17$58.00
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1/29/2026Boost Price Target$32.43$38.00Buy
Viatris Inc. stock logo
VTRS
Viatris
1/7/2026Set Price Target$12.40$16.00
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1/7/2026Set Price Target$46.21$55.00
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1/7/2026Boost Price Target$7.65$8.00Hold
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
11/7/2025Boost Price Target$42.86$48.00Buy
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
11/7/2025Lower Price Target$22.30$28.00Buy
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
5/28/2025Initiated Coverage$17.92$25.00Buy